| 產(chǎn)品名稱 | Z-138 |
|---|---|
| 商品貨號(hào) | B167178 |
| Organism | Homo sapiens, human |
| Tissue | Mantle cell lymphoma (B cell non-Hodgkin's lymphoma) |
| Cell Type | lymphoblast |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | mantle cell lymphoma |
| Age | 70 years |
| Gender | male |
| Ethnicity | Caucasian |
| Storage Conditions | liquid nitrogen vapor phase |
| Karyotype | This is a hyperdiploid human cell line of male origin with a modal chromosome number of 49 and a 4% polyploidy rate. Most of the cells examined contained the t(11;14)(q13;q32) derivative chromosome common to Mantle Cell Lymphoma. Other derivative chromosomes present in most of the examined cells included: del(5)(p15), der(9)t(9;?), der(14)t(8;14)?, and add(17p). Overall, the karyology was consistent with published data. |
| Images |  |
| Derivation | The Z-138 cell line was derived from a patient who initially was diagnosed with chronic lymphocytic leukemia (CLL). About 2 years later, the neoplasm had transformed into an aggressive, mature B-cell acute lymphocytic leukemia (B-cell ALL). According to the criteria of the current World Health Organization lymphoma classification, this neoplasm is best classified as mantle cell lymphoma, with blastoid transformation present in the terminal phase of disease. |
| Clinical Data | 70 years
Caucasian
male
The Z-138 cell line was derived from a patient who initially was diagnosed with chronic lymphocytic leukemia (CLL). About 2 years later, the neoplasm had transformed into an aggressive, mature B-cell acute lymphocytic leukemia (B-cell ALL). According to the criteria of the current World Health Organization lymphoma classification, this neoplasm is best classified as mantle cell lymphoma, with blastoid transformation present in the terminal phase of disease. |
| Antigen Expression | CD3-, CD5-, CD10-, CD19+, CD20+, CD23+, FMC7- (verified at ATCC) |
| Genes Expressed | CD3-, CD5-, CD10-, CD19+, CD20+, CD23+, FMC7- (verified at ATCC) |
| Comments | Z-138 cells have a complex karyotype, including the t(11;14)(q13;q32) abnormality, which is common in B-cell neoplasms.
These cells overexpress Cyclin D1. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium:
horse serum to a final concentration of 10%
|
| Subculturing | Cultures can be maintained by the addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 x 105 to 2 x 105 viable cells/mL. Do not allow the cell concentration to exceed 3 x 106 cells/mL. Subcultivation ratio: A subcultivation ratio of 1:5 to 1:15 is recommended.
Medium renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation | Freeze medium: horse serum 90%; DMSO, 10% liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile | Amelogenin: X,Y CSF1PO: 10,11 D13S317: 9,12 D16S539: 11 D5S818: 11,13 D7S820: 8 TPOX: 8 THO1: 6 vWA: 15,18 |
| Population Doubling Time | approximately 24 hours |
| Name of Depositor | Z Estrov |
| Year of Origin | August 1990 |
| References | Estrov Z, et al . Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leuk. Res.:22 (4):341-353, 1998. PubMed 9669839 Medeiros LJ, et al. Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. Leuk. Res. 30(4):497-501, 2006. PubMed 16203034 Tucker CA, et al. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk. Res. 30: 449-457, 2006. PubMed: 16183118 |
| 序號(hào) | 文章標(biāo)題 | 操作 |
|---|---|---|
| 1 | ATCC細(xì)胞運(yùn)輸和處理 | 查看詳情 |
| 2 | 其他海外品牌代理 | 查看詳情 |
| 3 | ATCC代理 | 查看詳情 |
| 4 | 購(gòu)買須知 | 查看詳情 |
| 5 | 訂購(gòu)流程 | 查看詳情 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
